Items Tagged ‘bortezimib’

April 27th, 2015

Study Demonstrates Superiority Of Kyprolis® over Velcade® in Patients With Relapsed Multiple Myeloma


The results from a planned interim analysis of the Phase 3 head-to-head clinical trial ENDEAVOR evaluating Kyprolis® (carfilzomib in combination with low-dose dexamethasone versus Velcade® (bortezomib) and low-dose dexamethasone have demonstrated that the Kyprolis® treated patients lived twice as long without their disease worsening. Multiple myeloma is a cancer of plasma cells, which are a […]

View full entry

Tags: bortezimib, carfilzomib, ENDEAVOR, kyprolis, Multiple Myeloma, News, velcade